Reference articles, expert tips and information for control of costly reproductive and respiratory diseases
Video, audio segments with practicing veterinarians enhance website user’s experience
Available at www.vira-shield.com
Greensboro, NC, September 13, 2011—Novartis Animal Health U.S., Inc. has created a new, multi-media website exclusively for Vira Shield®, the number one selling inactivated cattle vaccine in the U.S. Vira Shield provides broad-spectrum protection from the most common reproductive and respiratory diseases affecting U.S. beef and dairy cattle today.
The website, www.vira-shield.com, includes information tailored specifically for beef producers, dairy producers and veterinarians. For producers, the disease information, vaccination guidelines and expert management tips can be leveraged in preventive health programs that drive better performance. For veterinarians, the site includes a library of scientific research papers and technical bulletins that are easily accessible for quick reference.
Visitors to the Vira Shield website can also access video and audio clips from producers and practicing veterinarians who face different cattle health challenges based on their geographic region and type of operation or practice.
“At Novartis Animal Health, our focus is really on prevention,” said Doug Scholz, DVM, director of veterinary services. “Our goal is to help beef and dairy producers minimize the incidence of disease and economic burdens that come with managing and treating sick animals. All of the tools and information we’ve included on www.vira-shield.com are designed to support producers and veterinarians in their efforts to maintain healthy, top-performing herds.”
Vira Shield is available in nine different combinations that contain up to 13 antigens in one ready-to-use bottle. It is the only vaccine to feature 3-way protection against the predominant disease affecting U.S. cattle—bovine viral diarrhea virus (BVD). It also provides protection against bovine respiratory syncytial virus (BRSV), infectious bovine rhinotracheitis (IBR), parainfluenza Type 3 (PI3), Lepto hardjo-bovis and vibriosis.
Vira Shield is safe for use in all cattle, including pregnant cows and heifers, regardless of their age or previous vaccination history. To learn more about Vira Shield and cattle health management tips that drive maximum performance, visit www.vira-shield.com and contact your Novartis Animal Health representative.
The foregoing release contains forward-looking statements that can be identified by terminology such as "can," "goal," or similar expressions, or by express or implied discussions regarding potential future revenues from Vira Shield. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Vira Shield will achieve any particular levels of revenue in the future. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Headquartered in Greensboro, NC, Novartis Animal Health US, Inc. researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Part of the Basel, Switzerland-based Novartis Animal Health global organization, the US business is the largest of the 40 countries where Novartis Animal Health operates. For more information about Novartis Animal Health US, Inc., please consult www.ah.novartis.us.
Novartis Animal Health US, Inc. is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group’s continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.